SMA

EQS-News: SMA Group concludes the 2023 fiscal year extremely successfully with strong fourth quarter in the Large Scale & Project Solutions segment

Retrieved on: 
Mercredi, mars 13, 2024

The figures report that the SMA Group’s sales significantly rose by 78.6% year on year to €1,904.1 million (2022: €1,065.9 million).

Key Points: 
  • The figures report that the SMA Group’s sales significantly rose by 78.6% year on year to €1,904.1 million (2022: €1,065.9 million).
  • Earnings before interest, taxes, depreciation and amortization (EBITDA) increased even sharply to €311.0 million from €70.0 million in the 2022 fiscal year.
  • Earnings before interest and taxes (EBIT) rose from €31.9 million in the 2022 fiscal year to €269.5 million (EBIT margin in 2023: 14.2%; 2022: 3.0%).
  • “In the fourth quarter of 2023, we once again significantly increased sales in the Large Scale & Project Solutions segment and even exceeded the upper end of our sales forecast,” said SMA CEO Jürgen Reinert.

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Retrieved on: 
Mercredi, mars 6, 2024

* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).

Key Points: 
  • * The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).
  • The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA.
  • These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 3-6, 2024).
  • “Our evolving understanding of gene therapy indicates there may be an opportunity for better outcomes,” said Crystal Proud, M.D., Pediatric Neurologist at Children’s Hospital of the King’s Daughters.

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

Retrieved on: 
Vendredi, mars 1, 2024

ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.

Key Points: 
  • ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.
  • ClC-1 inhibition could be a possible mechanism to improve muscle fiber activation to address muscle weakness and fatigue in neuromuscular diseases.
  • Details of NMD Pharma’s poster presentations are below:
    The 4th Scientific International Congress on SMA is taking place in Ghent, Belgium, from 14-16 March.
  • : NMD Pharma be presenting one poster and one oral presentation at the congress.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Mercredi, février 28, 2024

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported fourth quarter and full year 2023 financial and operating results.

Key Points: 
  • ET today -
    LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported fourth quarter and full year 2023 financial and operating results.
  • Novartis agreed to pay Voyager $80 million of consideration up front and $20 million for the purchase of newly issued equity in Voyager.
  • Collaboration Revenues: Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023, compared to $(1.6) million for the same period in 2022.
  • ET to discuss the fourth quarter and full year 2023 financial and operating results.

BlackRock to Acquire SpiderRock Advisors

Retrieved on: 
Vendredi, mars 8, 2024

BlackRock (NYSE: BLK) has agreed to acquire the remaining equity interest in SpiderRock Advisors (“SRA”), a leading provider of customized option overlay strategies in the U.S. wealth market.

Key Points: 
  • BlackRock (NYSE: BLK) has agreed to acquire the remaining equity interest in SpiderRock Advisors (“SRA”), a leading provider of customized option overlay strategies in the U.S. wealth market.
  • “By giving BlackRock more SMA capabilities, this acquisition will enable us to meet growing demand from wealth managers for personalized, tax-efficient portfolios.
  • “We are thrilled to fully join the BlackRock team, and to broaden access to SpiderRock Advisors’ options management solutions for both taxable and tax-exempt investors,” said Eric Metz, President and Chief Investment Officer of SpiderRock Advisors.
  • Jones Day acted as legal counsel for SpiderRock Advisors, LLC.

Scholar Rock to Participate in Upcoming Investor Conferences

Retrieved on: 
Mercredi, février 28, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March:

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March:
    TD Cowen 44th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 9:10 a.m.
  • BMO Biopharma Spotlight Series: Obesity Day: Scholar Rock is scheduled to participate in a panel discussion on Wednesday, March 20 in New York City.
  • A live webcast of the Cowen event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

Global Times: How two sessions serve as bridge between people and government, help authorities formulate policies

Retrieved on: 
Vendredi, mars 8, 2024

Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.

Key Points: 
  • Various localities in the country are implementing policies on medication, health insurance and research according to the catalog.
  • In 2021, China also for the first time included a rare disease treatment in its National Reimbursement Drug List.
  • These moves together benefited thousands of Chinese suffering from rare diseases, including spinal muscular atrophy (SMA) patient Zhang Jianuo and his parents.
  • Motions and proposals during the two sessions are crucial pathways for addressing issues impacting people's livelihood, and they're becoming increasingly effective.

Zephyr Releases PSN Top Guns List for Q4 2023, Highlighting Best-In-Class Separate Accounts, Managed Accounts and Managed ETF Strategies

Retrieved on: 
Mercredi, mars 6, 2024

NEW YORK, March 6, 2024 /PRNewswire/ -- Zephyr, a subsidiary of Informa plc (LSE: INF), and a recognized leader in investment management technology for wealth managers and advisors, has released its highly anticipated PSN Top Guns List for Q4 2023. The list is an important reference for plan sponsors, investors and asset managers, showcasing the best performing separate accounts, managed accounts and managed ETF strategies each quarter.

Key Points: 
  • The list is an important reference for plan sponsors, investors and asset managers, showcasing the best performing separate accounts, managed accounts and managed ETF strategies each quarter.
  • PSN celebrates 40 years in 2024 as the longest running SMA database in the world.
  • The complete list of PSN Top Guns and an overview of the methodology, can be found here .
  • If you would like to learn more about becoming a part of the PSN database or would like to subscribe to PSN data, visit PSN .

Why some RNA drugs work better than others

Retrieved on: 
Mercredi, mars 6, 2024

CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.

Key Points: 
  • CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.
  • To better understand how this drug works, the Kinney and Krainer labs analyzed risdiplam's interactions with RNA.
  • "Our new study provides insights into the action and specificity of splice-modifying drugs," Krainer says.
  • "This should facilitate the development of more effective drugs and drug combinations for a variety of diseases."

Fairview Microwave Unveils RF Fixed Attenuators and Terminations Up to 26 GHz

Retrieved on: 
Mardi, février 27, 2024

IRVINE, Calif., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Fairview Microwave, an Infinite Electronics brand and a leading provider of RF, microwave and millimeter-wave products, has announced the launch of its latest product line: RF fixed attenuators and terminations with an operational frequency reaching up to 26 GHz.

Key Points: 
  • IRVINE, Calif., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Fairview Microwave, an Infinite Electronics brand and a leading provider of RF, microwave and millimeter-wave products, has announced the launch of its latest product line: RF fixed attenuators and terminations with an operational frequency reaching up to 26 GHz.
  • "Our latest RF fixed attenuators and terminations exceed the market's expectations for performance, reliability and availability," said Product Line Manager Steven Pong.
  • "Our latest RF fixed attenuators and terminations exceed the market's expectations for performance, reliability and availability," said Product Line Manager Steven Pong.
  • Fairview's RF fixed attenuators and terminations are in stock and ready for immediate shipment with no minimum order quantity.